Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850398 | 0.97 | SLC15A1 (0.55) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL124385 | 0.97 | SLC15A1 (0.55) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL432780 | 0.97 | SLC15A1 (0.55) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29398213 | 0.95 | SLC15A1 (0.53) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| Glutamic Acid SCHEMBL7243656 | 0.93 | SLC1A1 (0.53) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| Alanine SCHEMBL4410297 | 0.91 | SLC15A1 (0.52) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8411886 | 0.91 | LTA4H (0.50) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8233964 | 0.89 | LTA4H (0.55) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16917221 | 0.89 | LTA4H (0.55) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10887282 | 0.89 | LTA4H (0.55) | SLC15A1LTA4HALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534670-B1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER REC TECH LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7235585-B2 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1534670-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CNDP2, PNP, APRT | SLC15A1 1759/4885LTA4H 420/4885ALDH1A1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.